The advanced facility brings globally benchmarked complement assays to Indian patients
Dr Lal PathLabs (DLPL) announced the launch of India’s first dedicated Complement Testing Laboratory, strengthening its position as India’s leading hub for autoimmune diagnostics. The advanced facility brings globally benchmarked complement assays to Indian patients, several for the first time in the country, helping doctors diagnose autoimmune, kidney, and recurrent infection related conditions faster, more accurately, and at earlier stages.
“Complement testing has long been underrepresented in India’s diagnostic landscape. By introducing functional and antibody-based complement assays such as C1q, C5, Factor B, Factor H antibody, AH50, and C1 INH functional, many for the first time in the country, we are enabling earlier and more precise insights into immune-mediated disease. This bridges the gap between research and routine clinical care,” said Dr Vandana Lal, Executive Director, Dr Lal PathLabs.
“As a pioneer in specialized diagnostics, we are proud to offer India’s first comprehensive complement testing platform. This marks a major step toward faster diagnosis, better treatment decisions, and improved outcomes for millions living with autoimmune and kidney diseases” said Shankha Banerjee, CEO, Dr Lal PathLabs.
